Viridian Therapeutics, Inc.

NASDAQ (USD): Viridian Therapeutics, Inc. (VRDN)

Last Price

21.06

Today's Change

-0.12 (0.56%)

Day's Change

20.61 - 22.65

Trading Volume

1,562,467

Overview

Market Cap

1 Billion

Shares Outstanding

63 Million

Avg Volume

1,482,164

Avg Price (50 Days)

15.71

Avg Price (200 Days)

16.57

PE Ratio

-4.96

EPS

-4.25

Earnings Announcement

11-Nov-2024

Previous Close

21.18

Open

22.44

Day's Range

20.61 - 22.65

Year Range

10.925 - 24.18

Trading Volume

1,562,467

Price Change Highlight

1 Day Change

-0.57%

5 Day Change

-2.55%

1 Month Change

33.04%

3 Month Change

70.11%

6 Month Change

22.37%

Ytd Change

-5.77%

1 Year Change

23.52%

3 Year Change

97.01%

5 Year Change

54.63%

10 Year Change

-97.92%

Max Change

-98.97%

News and Blogs
Latest Hottest Following

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Biotechnology

Description:

Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for the treatment of TED. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was founded in 2006 and is headquartered in Waltham, Massachusetts.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment